European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update

Details

Serval ID
serval:BIB_B368242722F2
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 Update
Journal
Bone Marrow Transplant. 2010 Jul 26.
Author(s)
Maertens J Marchetti O Herbrecht R Cornely OA Flückiger U Frêre P Gachot B Heinz WJ Lass-Flörl C Ribaud P Thiebaut A Cordonnier C.
Publication state
Published
Issued date
07/2010
Peer-reviewed
Oui
Language
english
Abstract
Abstract
In 2005, several groups, including the European Group for Blood and Marrow Transplantation, the European Organization for Treatment and Research of Cancer, the European Leukemia Net and the Immunocompromised Host Society created the European Conference on Infections in Leukemia (ECIL). The main goal of ECIL is to elaborate guidelines, or recommendations, for the management of infections in leukemia and stem cell transplant patients. The first sets of ECIL slides about the management of invasive fungal disease were made available on the web in 2006 and the papers were published in 2007. The third meeting of the group (ECIL 3) was held in September 2009 and the group updated its previous recommendations. The goal of this paper is to summarize the new proposals from ECIL 3, based on the results of studies published after the ECIL 2 meeting: (1) the prophylactic recommendations for hematopoietic stem cell transplant recipients were formulated differently, by splitting the neutropenic and the GVHD phases and taking into account recent data on voriconazole; (2) micafungin was introduced as an alternative drug for empirical antifungal therapy; (3) although several studies were published on preemptive antifungal approaches in neutropenic patients, the group decided not to propose any recommendation, as the only randomized study comparing an empirical versus a preemptive approach showed a significant excess of fungal disease in the preemptive group.Bone Marrow Transplantation advance online publication, 26 July 2010; doi:10.1038/bmt.2010.175.
PMID: 20661235 [PubMed - as supplied by publisher]
Open Access
Yes
Create date
11/03/2011 12:20
Last modification date
18/09/2020 6:26
Usage data